h R

Rate of Treg cell inhibition by Sunitinib

0.227

day−1

[45]

K R

Rate of Treg cell depletion from chemotherapy toxicity

5.7 × 10 1

day−1

[45]

α 1

Determines the scope of influence of KRAS-mutant tumor cells Tcp in making tumor cells resistant to chemotherapy and in reducing the sensitizing role of Cetuximab and Panitumumab to chemotherapy

1 × 10 7

unitless

[25]

λ R

Efficacy of Sunitinib in inhibiting the immunosuppressive activity of Tregs

50.02

L mg−1

[45]

δ R

Chemotherapy toxicity on Tregs

2 × 10 1

L mg−1

[32]

η S

Rate of excretion and elimination of Sunitinib

0.277

day−1

[45]

a m

Growth rate of mutant tumor cells (colorectal cancer)

2.31 × 10 1

day−1

[32]

μ

Maximum mutation rate of wild-type tumor cells

4 × 10 5

day−1

[55]

K M

Concentration of Irinotecan chemotherapy that leads to a half-maximal rate of mutation of wild-type tumor cells Tw into irinotecan-resistant tumor cells Ti

1 × 10 3

mg L−1

Est.

δ T R

Efficacy of the second type of chemotherapy drug of killing irinotecan-resistant tumor cells

2 × 10 1

L mg−1

[32]

γ 2

Rate of excretion and elimination of the hypothetical chemotherapy drug

4.077 × 10 1

day−1

[32]

η F

Degradation rate of anti-TGF-beta (Fresolimumab)

0.033

day−1

Est. from [56]

b 2

Rate of loss of free TGF-β due to binding with anti-TGF-β

100

L mg−1 day−1

Est. from [56]

b 3

Rate of loss of free anti-TGF-β due to binding with TGF-β

2.5 × 10 13

L IU−1 day−1

Est. from [56]

λ M 0

Differentiation rate of M0 macrophages into an M1 or M2 macrophage

1 × 10 4

day−1

Est. from [31]